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Abstract Using synthetic Tn (GalNAc-O-Ser/Thr) glycopep-
tide models and a biosensor based on surface plasmon resonance
spectroscopy we have determined that isolectin B4 from Vicia
villosa (VVLB4) binds to one Tn determinant whereas the anti-
Tn monoclonal antibodies 83D4 and MLS128 require at least
two Tn residues for recognition. When an unglycosylated amino
acid is introduced between the Tn residues, both antibodies do not
bind. MLS128 affinity was higher on a glycopeptide with three
consecutive Tn residues. These results indicate that Tn residues
organized in clusters are essential for the binding of these
antibodies and indicate a different Tn recognition pattern for
VVLB4.
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1. Introduction
Aberrant glycosylation of tumor mucins results in expres-
sion of unusual glycosidic structures and exposure of the pep-
tide backbone [1]. The Tn determinant (GalNAcK-O-Ser/Thr),
normally cryptic in mucin-type O-glycans, is a tumor-associ-
ated marker which has attracted particular interest in cancer
biology: (a) it may be a useful diagnostic marker since it is
poorly expressed in normal tissues but is widely expressed in a
variety of adenocarcinomas [2] ; (b) a direct correlation has
been shown between carcinoma aggressiveness and the density
of this antigen, e.g. extent of tissue spread and vessel invasion
[3]; (c) Tn antigen can be recognized by the immune system
[4] and thus provides a potentially important therapeutic tar-
get [5] ; (d) Tn has been implicated in the metastasis of tumor
cells [6]. Furthermore, Tn is found in the envelope glycopro-
tein gp120 of di¡erent HIV isolates where it constitutes an
immunoneutralization epitope [7].
The Tn antigen was characterized using both monoclonal
antibodies (mAb) [8^11] and lectins [12,13], but the speci¢c
reactivities displayed by these proteins are not identical. This
raises questions about the exact molecular structure of the
epitope. For example, it would be of interest to determine if
these Tn-binding proteins require more complex epitopes than
the GalNAc-Ser/Thr structure such as the involvement of oth-
er amino acids in the antigenic determinant, conformational
elements or high density of Tn residues. It has been reported
that clusters of Tn are an essential part of the epitope recog-
nized by the mAb MLS128 (an IgG), which is poorly reactive
or unreactive with glycopeptides bearing unclustered Tn struc-
tures [14]. Under di¡erent conditions of deglycosylation of
Tn-rich mucins we have previously shown [11] that binding
of mAb 83D4 (an IgM) to the mucin was much more a¡ected
by mild alkaline treatment than was the isolectin B4 from
Vicia villosa (a lectin with speci¢city for Tn antigen).
Because of the potential involvement of Tn antigen in the
metastatic process and its use as target for immunotherapy, a
de¢nition of the exact nature of the epitope is important. The
notion of epitope is a functional concept and binding mea-
surements are essential for the de¢nition of the Tn epitope. In
this paper we describe and measure the a⁄nity constants of
Tn clusters with two monoclonal antibodies, MLS128 and
83D4, as well as with the isolectin B4 from Vicia villosa
(VVLB4) using well-de¢ned glycopeptide models and a bio-
sensor based on surface plasmon resonance spectroscopy
(BIAcore1).
2. Materials and methods
2.1. Monoclonal antibodies and isolectin B4 from V. villosa
The mAb 83D4 (IgM) was produced from a mouse immunized with
cell suspensions obtained from formalin-¢xed para⁄n-embedded sec-
tions of an invasive human breast carcinoma [15]. mAb was precipi-
tated from ascitic £uids by dialysis against demineralized water at
4‡C, dissolved in a small volume of 0.5 M NaCl in phosphate bu¡er
saline (PBS), applied to a Sephacryl S-200 gel column (2.5U85 cm),
and eluted with PBS. IgM was excluded from the gel and recovered in
the ¢rst elution peak. The mAb MLS128 (IgG1), established by im-
munizing mice with human colonic cancer cells (LS180) [16], was
puri¢ed by a⁄nity chromatography on protein A-Sepharose. The
Tn-binding isolectin B4 from V. villosa seeds was purchased from
Sigma Chemical Co., St Louis, MO, USA. The purity of the three
anti-Tn proteins was demonstrated by SDS^PAGE analysis.
2.2. Synthesis of Tn glycopeptides
2.2.1. General methods. Reagents were purchased from Aldrich or
Sigma. All the solvents were high grade and dry. CH2Cl2 was distilled
over P2O5 before use. Glycosylated serine and threonine derivatives
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[Fmoc-Ser(K-GalNAc(OAc)3) and Fmoc-Thr(K-GalNAc(OAc)3)]
were prepared by classical methods [17,18] involving glycosylation
of NK-(£uoren-9-yl-methoxycarbonyl)-L-serine/threonine tert-butyl es-
ters [19,20] with 3,4,6-tri-O-acetyl-2-azido-2-deoxy-L-D-galactopyrano-
syl chloride (obtained from tri-O-acetyl-D-galactal [21]) using AgOTf
as catalyst [22] ; this condensation was followed by the reduction/ace-
tylation of the azido group in the 2-position [23]. At the end, the t-
butyl esters were deprotected in formic acid [24]. For the peptide
synthesis, Fmoc-protected amino acid derivatives and Wang resin
were obtained from Bachem or Novabiochem. When unglycosylated,
the side chains of the amino acids serine and threonine were protected
by a t-butyl group and the lysine residues by a t-butyloxycarbonyl
group. DMF and acetonitrile for HPLC were purchased from Merck.
The ¢nal compounds were puri¢ed by reverse phase high performance
liquid chromatography (HPLC) using a Perkin-Elmer pump system
with a UV detector (230 nm). A column (250U10 mm) of Nucleosil
C18 (5 mm, 300 Aî ) was used and the products were eluted with a
gradient of MeCN/0.1% tri£uoroacetic acid bu¡er during 20 min (£ow
rate 6 ml/min). Mass spectra were measured by electrospray on a
Platform spectrometer (VG-Biotech-Micromass, Manchester, UK).
Amino acid analyses were obtained using a Beckman 6300 analyzer,
after hydrolysis of the peptides with 6 N HCl at 110‡C in sealed glass
tubes for 20 h.
2.2.2. Solid phase syntheses. The solid phase peptide and glyco-
peptide syntheses were performed manually using the standard Fmoc
chemistry protocol on a polystyrene resin functionalized with p-ben-
zyloxybenzyl alcohol (Wang resin) esteri¢ed with a glycine residue.
The NK-Fmoc amino acids (carrying standard side chain protective
groups) and the glycosylated building blocks (3 equivalents) were in-
corporated to the peptide chain using TBTU/HOBT/DIEA 1/1/1.7 as
an activating agent and DMF as solvent [25]. The couplings were
monitored by the Kaiser test [26] and usually completed within 20
min. All Fmoc cleavages were carried out by treatment of the resin
with 20% piperidine in DMF (2 min then 8 min). Following each
deprotection, the resin was successively rinsed with DMF, CH2Cl2,
DMF. At the end of the synthesis, the resin was extensively washed
with DMF and CH2Cl2, dried, and treated with an aqueous TFA
solution (95%) for 2 h. After ¢ltration of the resin, the solution was
concentrated and the crude product precipitated with diethyl ether.
The precipitate was ¢ltered, dissolved in water and lyophilized. The
peptides were puri¢ed by HPLC (gradient from 10% to 40% in 20
min) and obtained with an overall yield of 25%. Finally the acetyl
groups of the sugar moiety were removed by adding, dropwise, a
solution of 1% MeONa (pH 10.8). After 8 h, methanol was evapo-
rated and the medium neutralized to neutral pH. The peptides were
puri¢ed by HPLC on a reverse phase column (C18) using a gradient of
0.1% TFA in water (solution A) and acetonitrile (solution B), and
characterized by mass spectrometry and amino acid analysis.
2.2.3. Characteristics of peptides. Tn0 : Lys-(Gly)4-Ser-Thr-Thr-
(Gly)3, elution with a gradient from 0% to 17% (retention time
8.4 min); ESMS: 834.47 (calc 834.38). Amino acid analysis: Lys
1.06 (1), Gly 6.66 (7), Ser 0.85 (1), Thr 2.
Tn1 : Lys-(Gly)4-Ser(K-GalNAc)-Thr-Thr-(Gly)3, elution with a
gradient from 0% to 17% (retention time 8.6 min); ESMS 1037.64
(calc 1037.46). Amino acid analysis: Lys 1, Gly 6.97 (7), Ser 0.87 (1),
Thr 1.85 (2).
Tn2 : Lys-(Gly)4-Ser(K-GalNAc)-Thr(K-GalNAc)-Thr-(Gly)3, elu-
tion with a gradient from 0% to 15% (retention time 8.8 min);
ESMS 1240.41 (calc 1240.54). Amino acid analysis: Lys 1.07 (1),
Gly 7, Ser 0.93 (1), Thr 1.90 (2).
Tn3 : Lys-(Gly)4-Ser(K-GalNAc)-Thr(K-GalNAc)-Thr(K-GalNAc)-
(Gly)3, elution with a gradient from 0% to 10% (retention time
11.6 min); ESMS 1443.86 (calc 1443.62). Amino acid analysis: Lys
1, Gly 6.48 (7), Ser 0.93 (1), Thr 1.74 (2).
Tn2t : Lys-(Gly)4-Ser(K-GalNAc)-Thr-Thr(K-GalNAc)-(Gly)3, elu-
tion with a gradient from 0% to 8% in 10 min (retention time
9.6 min); ESMS 1240.49 (calc 1240.54). Amino acid analysis: Lys 1,
Gly 6.68 (7), Ser 0.89 (1), Thr 1.85 (2).
Tn2p : Lys-(Gly)4-Ser(K-GalNAc)-Pro-Thr(K-GalNAc)-(Gly)3, elu-
tion with a gradient from 0% to 8% (retention time 15.2 min);
ESMS 1236.80 (calc 1236.55). Amino acid analysis: Lys 1, Gly 6.88
(7), Ser 0.90 (1), Thr 0.92 (1), Pro 1.03 (1).
2.3. Surface plasmon resonance studies
The BIAcore1 biosensor (Pharmacia, Uppsala, Sweden), which
uses surface plasmon resonance detection and permits real-time ki-
netic analysis of two interacting species [27], was used to measure
the binding kinetics of Tn to the proteins. Immobilization of peptides
on the sensor surface (a CM5 dextran sensor chip) was performed
through lysine residue according to standard procedures described
previously [28]. The dextran layer of the sensor chip was ¢rst activated
by injecting 35 Wl of 0.2 M N-ethyl-N-(3-diethylaminopropyl)carbo-
diimide and 0.05 M N-hydroxysuccinimide. Next, each peptide (30 Wl)
at a concentration of 2.5 mg/ml in 10 mM sodium acetate, pH 4.5,
was injected. Excess reactive groups were blocked by injection of 30 Wl
of 1 M ethanolamine, pH 8.5. All binding analyses were conducted in
HBS bu¡er (10 mM HEPES pH 7.4, 0.15 M NaCl, 3.4 WM EDTA,
0.005% surfactant P20) at a £ow rate of 5 Wl/min at 25‡C. The surface
was regenerated with 1 M NaCl with no loss of activity as re£ected by
the identical binding evidenced when an equivalent sample was rein-
troduced in the next cycle (data not shown). Samples for binding
analysis were diluted into the binding bu¡er (HBS). Kinetic studies
were performed by injecting 20 Wl of each protein, at a £ow of 5 Wl/
min. Each anti-Tn protein was analyzed at ¢ve di¡erent concentra-
tions (0.062, 0.125, 0.250, 0.5, and 1.0 WM). The kinetic constants for
association (KA) and dissociation (KD) were evaluated using BIAeval-
uation 3.0 software supplied by the manufacturer (Pharmacia).
3. Results and discussion
Trying to better understand the molecular structure of what
is called the Tn epitope, we have performed kinetic studies by
surface plasmon resonance spectroscopy to evaluate the a⁄n-
ities between Tn and di¡erent Tn-binding proteins. In order to
analyze the clustering e¡ect of GalNAc residues O-linked to
serine or threonine, we have synthesized three Tn glycopep-
tides (Tn1, Tn2 and Tn3) as well as the Tn-free peptide (Tn0)
as a control. The peptide backbone sequence is made of gly-
cine residues to minimize steric hindrance and side chain in-
teractions. An additional N-terminal lysine residue was intro-
duced for binding to the sensor surface. For the kinetic
analysis, each Tn-binding protein (mAbs MLS128, 83D4
and lectin VVLB4) was added at ¢ve concentrations (0.062^
1.0 WM) to each £ow cell ; association and dissociation were
monitored in real time. As can be seen in the representative
sensorgrams, VVLB4 bound Tn1, Tn2 and Tn3 glycopeptides
(Fig. 1A), while no binding to the GalNAc-free peptide (Tn0)
was observed. Using the same £ow cells we found that anti-Tn
mAbs MLS128 and 83D4 did not bind to the GalNAc-free
Table 1




















VVLB4 2.5U104 5.4U1033 2.2U1037 1.4U104 4.5U1033 3.2U1037 2.7U104 3U1033 1.1U1037
83D4 ^ ^ ^ 7.6U105 7.6U1033 1U1038 2.1U105 2.5U1033 1.2U1038
MLS128 ^ ^ ^ 2.7U104 3.6U1033 1.3U1037 4.5U104 1.1U1033 2.4U1038
Each parameter was determined as described in Section 2, evaluating each protein (mAbs MLS128, 83D4 and lectin VVLB4) at ¢ve concentra-
tions (0.062, 0.125, 0.250, 0.5, and 1.0 WM).
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and the Tn1 peptides, but both did interact with the Tn2 and
Tn3 peptides (Fig. 1B,C). These results indicate one Tn resi-
due is enough for VVLB4 binding whereas the anti-Tn anti-
bodies require at least two consecutive Tn residues for recog-
nition.
The association, dissociation and a⁄nity constants for the
interactions between Tn glycopeptides and proteins are shown
in Table 1. It appears that the VVLB4 binding does not de-
pend on the density of the Tn determinant since the three
glycopeptides Tn1, Tn2 and Tn3 show similar a⁄nities. The
mAb 83D4 recognizes both the di-Tn and the tri-Tn glyco-
peptides, while the mAb MLS128, although reactive with the
di-Tn glycopeptide, has a higher a⁄nity with the tri-Tn gly-
copeptide Tn3.
These observations suggest that a dimeric Tn cluster ap-
pears to be the ‘minimum recognized structure’ for MLS128
and 83D4 antibodies, and raise the question whether these
monoclonal antibodies could bind to peptides where the Tn
residues are not consecutive in the peptide sequence. To in-
vestigate this aspect, we synthesized glycopeptides Tn2t and
Tn2p where the two Tn residues are separated by one ungly-
cosylated amino acid. In order to evaluate the in£uence of the
unglycosylated threonine in peptide Tn2t, proline was intro-
duced between the two Tn units (peptide Tn2p). The results of
the kinetics studies using the three Tn binding proteins are
shown in the Table 2. It is observed that when an unglycosy-
lated amino acid is introduced between the Tn residues, both
MLS128 and 83D4 do not bind. This result clearly shows that
two consecutive Tn structures are essential for the binding of
these antibodies. By contrast, VVLB4 bound to the glycopep-
tides Tn2t and Tn2p with a⁄nities similar to those observed
with the glycopeptides Tn1, Tn2 and Tn3. Considering that in
Tn1 glycopeptide GalNAc is O-linked to a serine residue, and
that in both Tn2t and Tn2p glycopeptides one GalNAc is
O-linked to serine and the other to threonine, these results
indicate that the unreactivity of anti-Tn monoclonal antibod-
ies on mono-Tn glycopeptide motifs is independent of whether
GalNAc is O-linked to serine or threonine residues.
Our results using mAb MLS128 agree with the previous
observation that this antibody preferentially binds with a clus-
ter of three adjacent serine or threonine residues, each linked
to GalNAc by a K linkage, but does not recognize mono-Tn
glycopeptides [14]. Here, using synthetic model Tn glycopep-
tides and a biosensor based on surface plasmon resonance
spectroscopy, we show that mAb MLS128 also binds glyco-
peptides bearing two adjacent Tn residues, although with less
a⁄nity. Furthermore, mAb 83D4 binds with similar a⁄nity to
dimeric as well as to trimeric clusters of Tn, suggesting that
the ¢ne speci¢city of both anti-Tn monoclonal antibodies is
not the same. The clustering e¡ect appears to be not restricted
to the epitope identi¢ed by antibodies. Recently it has been
reported that Tn clusters are essential for the recognition by
the Tn-speci¢c human macrophage C-type lectin, which reacts
poorly with glycopeptides bearing mono-Tn motifs [29].
The clustering e¡ect has also been reported on anti-sialyl-
Tn monoclonal antibodies. Reddish et al. [30] have shown
that some antibodies recognize the sialyl-Tn as an isolated
structure (mAb 195.3) whereas some others need a cluster
for binding (mAbs B72.3 and CC49). Recently, Tanaka et
al. [31] found that a cluster composed of four sialyl-Tn anti-
gens is the essential epitopic structure for mAb MLS132. The
biological role of clustered versus single Tn or sialyl-Tn epi-
topes on cancer cells is still not understood. Ogata et al. [32]
reported that sialyl-Tn clusters appear during malignant
transformation of human colonic mucosa. The ability to syn-
thesize monomer or cluster of Tn/sialyl-Tn structures on mu-
cin polypeptide backbones could depend in part on the se-
quence of O-glycosylation sites of the apomucin, as well as
on the repertoire and speci¢city of glycosyltransferases re-
quired for Tn/sialyl-Tn synthesis that exist in normal versus
Fig. 1. Sensorgrams showing the interactions between the three Tn-
binding proteins and the synthetic Tn glycopeptides. In these repre-
sentative sensorgrams each protein was injected onto the surface-
bound glycopeptide at 0.5 WM. A: Isolectin B4 from V. villosa
seeds. B: mAb 83D4. C: mAb MLS128.
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cancerous cells. The initial transfer of GalNAc to the apomu-
cin peptide can be performed by several UDP-GalNAc:poly-
peptide N-acetylgalactosaminyl transferases (EC 2.4.1.41)
which control the O-linked glycosylation [33]. Studies using
the MUC1 tandem repeat peptide as acceptor showed that
site-speci¢c glycosylation could regulate the addition of Gal-
NAc to Ser/Thr at adjacent or distant positions [34], indicat-
ing that the addition of GalNAc can be a¡ected by previous
glycosylation of other sites of the peptide substrate.
The fact that Tn binding exhibited by VVLB4 is not depen-
dent on the density of Tn determinants is in favor of di¡erent
Tn recognition patterns for this lectin and the two antibodies
studied, MLS128 and 83D4. These results, using model gly-
copeptides immobilized on a solid phase, are consistent with
the reactivity observed for two plant lectins (Salvia sclarea
and VVLB4) and mAb 83D4 using the same glycopeptides
but in solution [35]. In that case also, both lectins bind sim-
ilarly to Tn1, Tn2, Tn3 whereas mAb 83D4 only recognized
the di- and tri-Tn glycopeptides. As part of our structural
studies of Tn-binding proteins, we have constructed a single-
chain Fv fragment of the anti-Tn mAb 83D4, and have dem-
onstrated that this recombinant polypeptide retains Tn-bind-
ing properties [36]. The monoclonal antibodies directed
against four sialyl-Tn and mAb 83D4 use the same VH germ-
line gene segment, VHKTAG-1 [36], indicating that the heavy
chain plays a predominant role in determining the antigen
binding a⁄nity. Molecular modeling of the 83D4 molecule
indicated that the antibody-combining site might be primarily
de¢ned by the CDR H1 and H2 loops. The di¡erences in
speci¢city between anti-Tn and anti-sialyl-Tn antibodies could
be explained by signi¢cant sequence variations which occur in
both the light chain and the CDR H3 loop. On the other
hand, we have reported the amino acid sequence and the
crystal structure of the isolectin B4 from V. villosa seeds
[37]. The amino acid residues de¢ning the metal- and sugar-
binding sites of GalNAc-speci¢c lectins are highly conserved
in the VVLB4 structure, indicating that residues outside the
carbohydrate-binding pocket and/or quaternary association
determinants may modulate the a⁄nity for the Tn glycopep-
tide. Crystallographic studies of these Tn-binding proteins in
complex with various Tn-containing molecules are in prog-
ress, and should provide invaluable information about the
speci¢c recognition of Tn determinant. Furthermore, consid-
ering that the amino acid sequence near the O-linked GalNAc
could participate in the determinant identi¢ed by monoclonal
antibodies, we are evaluating several Tn glycopeptides in or-
der to determine the role of the peptide moiety on their Tn-
binding reactivity.
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